Howard, Frederick M. http://orcid.org/0000-0002-6039-1141
He, Gong
Peterson, Joseph R.
Pfeiffer, J. R.
Earnest, Tyler
Pearson, Alexander T.
Abe, Hiroyuki
Cole, John A.
Nanda, Rita
Funding for this research was provided by:
National Cancer Institute (F32-CA265232)
Conquer Cancer Foundation (2022YIA-6675470300)
National Institute of Dental and Craniofacial Research (K08-DE026500)
National Cancer Institute (U01-CA243075, 1P20-CA233307)
U.S. Department of Defense (BC211095P1)
Article History
Received: 12 May 2022
Accepted: 19 August 2022
First Online: 5 September 2022
Declarations
:
: JR Peterson, JR Pfeiffer, TE, and JAC are employed by SimBioSys, and are involved in the commercial development of the evaluated model representing a potential conflict of interest, but authors from SimBioSys were blinded to pathologic response and long-term outcome data to ensure objective evaluation of this model. RN reported grants from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics/Gilead, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, and Seattle Genetics outside the submitted work; and personal fees from Aduro, Cardinal Health, Clovis, Fujifilm, G1 Therapeutics, Genentech, Immunomedics/Gilead, Ionis, iTeos, MacroGenics, Merck, OncoSec, Pfizer, and Seattle Genetics. ATP is on the advisory board for Prelude Therapeutics.